Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxyurea treatment for sickle cell disease.

Martin H Steinberg1

  • 1Boston University School of Medicine, 88 E. Newton St., Boston, MA 02118, USA. msteinberg@medicine.bu.edu

Thescientificworldjournal
|June 14, 2003
PubMed
Summary

High fetal hemoglobin (HbF) levels are key to managing sickle cell disease complications. Hydroxyurea therapy shows promise by boosting HbF, but its long-term effects, especially in children, require further investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A New Fetal Hemoglobin-Related Phenotype in Sickle Cell Anemia.

American journal of hematology·2026
Same author

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

The New England journal of medicine·2026
Same author

Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing Therapies.

bioRxiv : the preprint server for biology·2026
Same author

PGC-1α agonism via oral administration of ZLN005 induces fetal hemoglobin and is antisickling in sickle mice.

Blood advances·2026
Same author

One cell at a time: HbF distribution in sickle cell disease.

Blood advances·2026
Same author

One cell at a time: HbF distribution in sickle cell disease.

Blood advances·2026

Area of Science:

  • Hematology
  • Pharmacology
  • Genetics

Background:

  • High fetal hemoglobin (HbF) levels inhibit sickle hemoglobin (HbS) polymerization, mitigating sickle cell disease (SCD) complications.
  • Therapeutic strategies aim to increase HbF or maintain HbF-producing erythroid precursors in adults.

Purpose of the Study:

  • To evaluate the efficacy of pharmacologic agents in increasing fetal hemoglobin (HbF) for sickle cell disease (SCD) treatment.
  • To assess the impact of hydroxyurea on HbF production and SCD complications.

Main Methods:

  • Hydroxyurea was administered to perturb erythroid precursor maturation, thereby promoting HbF production.
  • Clinical outcomes, including hemoglobin concentration and SCD complications, were monitored.

Main Results:

  • Hydroxyurea treatment increased total hemoglobin levels.
  • Significant reductions in vaso-occlusive complications, such as pain and acute chest syndrome, were observed.
  • Mortality in adult patients with SCD was attenuated.

Conclusions:

  • Hydroxyurea represents a promising pharmacologic therapy for sickle cell disease, effectively increasing HbF and reducing complications.
  • The inconsistent effects and ongoing trials in pediatric populations highlight the need for further research into its long-term safety and efficacy, particularly when initiated early in life.

Related Experiment Videos